Clinical study initiated in January 2020 with birch pollen hypoallergen DM-101 was suspended in March. The main reason for suspension is that the corona virus epidemic has brought about restrictions in the operations at the study site.Read more »
Below you can find the latest news releases from Desentum.
The latest open access paper about our hypoallergen development is available at Nature Scientific Reports.Read more »
Desentum is about to initiate a first-in-human clinical trial with its birch pollen hypoallergen designed to improve immunotherapeutic treatment of birch pollen allergy. In a funding round arranged by Springvest Oy, the company raised 4 million euros that it intends to use for funding clinical...Read more »
Desentumin joukkorahoituskierros käynnistyi 17.9.2019Read more »
Preparations are currently being finalized for the first clinical study with DM-101 hypoallergen, Desentum’s lead product candidate for the treatment of birch pollen allergy.Read more »